CYP3A4 and sarcoma: Preliminary results show that RG7388 has pharmacodynamic efficacy with increased p53 pathway biomarkers, mild clinical side effects, and evidence of clinical efficacy with stable disease in patients with sarcoma for 17, 22, and 23+ months duration.30 In addition, phase I clinical trials are currently evaluating RG7388 as a single agent or in combination with cytarabine in patients with acute myelogenous leukemia (NCT01773408), as well as a trial looking at RG7388 in combination with posaconazole, a CYP3A4 inhibitor, in patients with refractory solid tumor malignancies (NCT01901172).